

KUMAR AMIT  
Form 4  
March 06, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
KUMAR AMIT

2. Issuer Name **and** Ticker or Trading  
Symbol

AEOLUS PHARMACEUTICALS,  
INC. [AOLS]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
12/28/2010

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

C/O AEOLUS  
PHARMACEUTICALS,  
INC., 26361 CROWN VALLEY  
PARKWAY, SUITE 150

(Street)

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)

☒ Form filed by One Reporting Person

☐ Form filed by More than One Reporting  
Person

MISSION VIEJO, CA 92691

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control  
number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: KUMAR AMIT - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Option (right to buy)	\$ 0.6	12/28/2010		A		3,750		<u>(1)</u>	12/28/2020	Common Stock	3,750
Non-qualified Stock Option (right to buy)	\$ 0.8	02/10/2011		A		3,750		<u>(1)</u>	02/10/2021	Common Stock	3,750
Non-qualified Stock Option (right to buy)	\$ 0.5	04/13/2011		A		11,250		<u>(1)</u>	04/13/2021	Common Stock	11,250
Non-qualified Stock Option (right to buy)	\$ 0.4	05/16/2011		A		3,750		<u>(1)</u>	05/16/2021	Common Stock	3,750
Non-qualified Stock Option (right to buy)	\$ 0.54	06/13/2011		A		3,750		<u>(1)</u>	06/13/2021	Common Stock	3,750
Non-qualified Stock Option (right to buy)	\$ 0.44	08/11/2011		A		3,750		<u>(1)</u>	08/11/2021	Common Stock	3,750
Non-qualified Stock Option (right to buy)	\$ 0.4	11/07/2011		A		11,250		<u>(1)</u>	11/07/2021	Common Stock	11,250
Non-qualified Stock Option (right to buy)	\$ 0.4	12/14/2011		A		3,750		<u>(1)</u>	12/14/2021	Common Stock	3,750
Non-qualified Stock Option (right to buy)	\$ 0.35	02/10/2012		A		3,750		<u>(1)</u>	02/10/2022	Common Stock	3,750
Non-qualified Stock Option (right to buy)	\$ 0.31	03/20/2012		A		11,250		<u>(1)</u>	03/20/2022	Common Stock	11,250
Non-qualified Stock Option (right to buy)	\$ 0.3	05/14/2012		A		3,750		<u>(1)</u>	05/14/2022	Common Stock	3,750
Non-qualified	\$ 0.23	07/11/2012		A		11,250		<u>(1)</u>	07/11/2022	Common	11,250

Stock Option (right to buy)								Stock	
Non-qualified Stock Option (right to buy)	\$ 0.3	08/13/2012	A	3,750	<u>(1)</u>	08/13/2022	Common Stock	3,750	
Non-qualified Stock Option (right to buy)	\$ 0.35	10/09/2012	A	11,250	<u>(1)</u>	10/09/2022	Common Stock	11,250	
Non-qualified Stock Option (right to buy)	\$ 0.24	12/27/2012	A	3,750	<u>(1)</u>	12/27/2022	Common Stock	3,750	
Non-qualified Stock Option (right to buy)	\$ 0.25	02/12/2013	A	3,750	<u>(1)</u>	02/12/2023	Common Stock	3,750	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KUMAR AMIT C/O AEOLUS PHARMACEUTICALS, INC. 26361 CROWN VALLEY PARKWAY, SUITE 150 MISSION VIEJO, CA 92691	X			

## Signatures

/s/ John McManus, by power of attorney 03/06/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Option will vest in equal monthly installments over a period of twelve months from the date of grant, provided that the Director remains on the Board of Directors of the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.